Dominantly Inherited Alzheimer Network Trial
common.study.values.description
“Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation.”
The purpose of this study is to assess the safety, tolerability, biomarker and cognitive efficacy of investigational products in subjects who are known to have an Alzheimer's disease-causing mutation by determining if treatment with the study drug slows the rate of progression of cognitive impairment and improves disease-related biomarkers. This study also offers an observational component collecting cognitive assessment data until the availability of an enrolling drug treatment group, referred to as cognitive run-in (CRI).
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-no
Drug - Gantenerumab
Subcutaneously every 4 weeks at escalating doses
Drug - Solanezumab
Intravenous infusion every 4 weeks at escalating doses
Drug - Matching Placebo (Gantenerumab)
Subcutaneous injection of placebo every 4 weeks
Drug - Matching Placebo (Solanezumab)
Intravenous infusion of placebo every 4 weeks
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Phase II/III Randomized, Double-Blind, Placebo-Controlled, Cognitive Endpoint, Multi-Center Study of Potential Disease Modifying Therapies in Individuals at Risk for and With Dominantly Inherited Alzheimer's Disease
common.study.values.clinical-trial-id
NCT01760005
participant.views.study.view.id
Rb462e
